These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15490387)

  • 21. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.
    Schleuning WD
    Haemostasis; 2001; 31(3-6):118-22. PubMed ID: 11910176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract]   [Full Text] [Related]  

  • 23. Amediplase: CGP 42935, K2tu-PA, MEN 9036.
    BioDrugs; 2002; 16(5):378-9. PubMed ID: 12408743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
    Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Structure of the natural plasminogen activator (t-PA) and of reteplase. Controversies on thrombolytic therapy. 45th yearly session of the American College of Cardiology. Orlando, Fla. March 1996].
    Dtsch Med Wochenschr; 1996; 121(36 Suppl Fur Praxis):1-8. PubMed ID: 9401482
    [No Abstract]   [Full Text] [Related]  

  • 27. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolysis in acute pulmonary embolism: to whom, how much and how?
    Jezek V
    Eur Heart J; 1997 Jul; 18(7):1045. PubMed ID: 9243132
    [No Abstract]   [Full Text] [Related]  

  • 30. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.
    Freeman R; Niego B; Croucher DR; Pedersen LO; Medcalf RL
    Brain Res; 2014 May; 1565():63-73. PubMed ID: 24675027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute embolic stroke treated with rt-PA during elective coronary angiography].
    Ascer E; Lessa I; Caldas JG; Frudit ME; Pereira Mde B; Baruzzi AC
    Arq Bras Cardiol; 1996 Sep; 67(3):171-3. PubMed ID: 9181710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of acute ischemic stroke, Part 1.
    Fullerton T
    J Am Pharm Assoc (Wash); 1996 Oct; NS36(10):571-2. PubMed ID: 8908931
    [No Abstract]   [Full Text] [Related]  

  • 35. Thrombolytic therapy.
    Collen D; Lijnen HR
    Ann N Y Acad Sci; 1991; 614():259-69. PubMed ID: 1902640
    [No Abstract]   [Full Text] [Related]  

  • 36. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 37. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn Circ J; 1995 Aug; 59(8):556-64. PubMed ID: 7474300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M; Gardell SJ; Marder VJ
    Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.